Purpose Multiple-gene, next-generation sequencing panels are increasingly used to assess hereditary cancer risks of patients with diverse personal and family cancer histories. The magnitude of breast and ovarian cancer risk associated with many clinically tested genes, and independent of family cancer history, remains to be quantified.
INTRODUCTION
Next-generation sequencing has dramatically expanded the scope and speed of genetic testing for hereditary cancer risk while simultaneously reducing cost. 1, 2 These advances are most evident in the approach to suspected hereditary breast and ovarian cancer (HBOC) syndrome. After 20 years of testing for BRCA1/2 only, clinicians now increasingly order multiple-gene panels of six to . 100 genes. 3, 4 Panel tests have identified mutations in other cancer-associated genes in 5% to 15% of BRCA1/2-negative patients with suspected HBOC, [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] more than doubling the mutation detection rate. This has begun to broaden our understanding of gene-specific phenotype, as mutations are found unexpectedly among patients with a cancer not thought to be associated with a particular gene.
ATM, CHEK2, PALB2, NBN, and others. Questions regarding cancer risk have become especially pressing as decreasing costs have increased testing access for patients with a wider range of personal and family histories than previously required. 16 With some exceptions, [17] [18] [19] studies estimating cancer risks have been small and underpowered, yielding imprecise estimates. This is problematic because our understanding of a patient's cancer risk guides treatment recommendations for enhanced breast screening and preventive surgeries. [20] [21] [22] [23] [24] For example, risk-reducing salpingo-oophorectomy is indicated with a mutation that confers a 10-to 20-fold increase over the average ovarian cancer risk (an absolute risk of 20% to 40%), but may be excessive with a mutation causing only a two-fold elevation (an absolute risk of 2% to 4%). 20 Penetrance estimates adjusted for family history represent the magnitude of risk that is independently genetic. Adjusted penetrance may be estimated in an unbiased manner from clinical populations where factors related to ascertainment bias are well captured, and represent the magnitude of risk that is independently genetic. 25 These adjusted penetrance estimates are applicable to women with no family history of cancer and may inform personalized assessments that combine genetic risks with environmental and lifestyle risk factors.
With clinical uptake of multiple-gene panel testing increasing rapidly, cancer risk estimates that control for diverse family histories are urgently needed to inform genetic counseling. In this study, we analyzed a testing laboratory's data on germline sequencing with a 25-gene panel in a large, real-world cohort using two complementary methods to determine novel estimates of mutation penetrance adjusted for family history. Genetic Laboratories) for a panel of 25 genes  (APC, ATM, BARD1, BMPR1A, BRCA1, BRCA2,  BRIP1, CDH1, CDK4, CHEK2, MLH2, MSH2,  MSH6, MUTYH, NBN, P14ARF, P16, PALB2,  PMS2, PTEN, RAD51C, RAD51D, SMAD4,  STK11 , and TP53). 26 Informed consent for clinical testing was obtained and clinical information was collected on the test requisition forms (TRFs). Patient data were deidentified and no additional information was obtained from patients or providers. As such, this analysis was not subject to ethics board review.
METHODS

Patients and Hereditary Cancer Testing
Variants were classified using American College of Medical Genetics and Genomics recommendations, with supporting linkage, biochemical, clinical, functional, and statistical data used for specific missense and intronic alterations. [27] [28] [29] Pathogenic variants are those that receive a laboratory classification of Deleterious or Suspected Deleterious. For this analysis, only biallelic mutations in MUTYH were considered. Classifications used in the analysis matched those reported clinically.
Clinical information from provider-completed TRFs included ancestry, personal and family cancer history, cancer type(s), and age(s) at diagnosis. Patients were excluded from analysis if they had an incomplete TRF, if they had testing using the 25-gene panel after receiving negative test results from a single/limited gene panel, or if results suggested mosaicism. No patient was excluded on the basis of race/ethnicity, age, or other characteristics.
Statistical Methods
All analyses were conducted using R version 3.0.2.
30 Two-sided P values are reported. Given that we had prior hypotheses about the sequenced genes, no adjustments were made for multiple testing.
We used two different statistical methods to quantify adjusted risks of invasive ductal carcinoma of the breast (BC) and invasive epithelial ovarian cancer (OC) associated with mutations in panel genes. The primary method was multivariable logistic regression modeling. The secondary method was matched case-control analysis. Both methods produce adjusted odds ratios (ORs), which estimate the relative risks conferred by mutations after accounting for other risk factors. These ORs represent the overall penetrance of mutations in each gene with respect to BC and OC. For genes associated with childhood mortality (eg, TP53 and STK11), the penetrance estimates represent BC and OC risks among mutation carriers who survive to adulthood.
Multivariable Logistic Regression Models
For each gene, we constructed two multivariable models to estimate (1) BC risk and (2) OC risk. BC and OC history were modeled as dependent variables. Independent variables included mutation status for the gene of interest, age, ancestry, personal and family cancer histories associated with HBOC, and Lynch and adenomatous polyposis colon cancer syndromes. CIs and P values were calculated on the basis of Wald statistics.
Personal cancer variables were coded as binary (ever or never affected). Models predicting BC included an independent variable for OC and vice versa. Familial cancers were coded as numeric counts of diagnoses, weighted by degree of relatedness. Additional details regarding the coding of variables are provided in the Data Supplement.
Matched Case-Control Analyses
Cases were defined as female patients with a single diagnosis of BC or OC. Controls were women with no cancer history at the time of genetic testing. Cases and controls were matched 1:1 according to age (6 3 years), ancestry (exact match), and family cancer history (breast, ovarian, colon, uterine). P values, ORs, and CIs were calculated with the exact McNemar's test.
Mutation status, age, and ancestry were coded as for models (Data Supplement). Familial BC was grouped into one of four categories: (1) at least one first-degree relative (FDR) with BC before the age of 50 years; (2) at least one FDR with BC at the age of 50 years or older; (3) at least one second-degree relative (SDR) with BC; and (4) none of the above. Familial OC was grouped into one of three categories: (1) at least one FDR with OC; (2) at least one SDR with OC; and (3) none of the above. For tests of OC associations, we included an extra three-level matching variable for familial colon and uterine cancer: (1) at least one FDR with colon or uterine cancer before the age of 50 years; (2) at least one FDR with colon or uterine cancer at the age of 50 years or older; and (3) none of the above.
Sensitivity Analysis
Age-specific cumulative BC risks on the basis of adjusted penetrance were compared with estimates for BRCA1 and BRCA2 on the basis of literature. [31] [32] [33] [34] [35] Cumulative risks were calculated according to the product-limit method, 36 with agespecific incidences estimated as the product of agespecific ORs and general population incidences. Age-specific ORs were calculated by subsetting to the age categories reported by Satagopan et al 35 (, 40, 40 to 49, and > 50 years), and were combined with age-specific SEER 37 incidence rates from 2009 to 2013 in 5-year intervals.
The magnitude of potential bias that could result from differential under-or over-reporting of family histories in cases versus controls was also investigated. Our hypothesis was that family histories may be over-reported among unaffected controls to meet insurance coverage criteria for genetic testing and/or under-reported among affected cases. Using BRCA1 and PALB2 as widely studied examples, we modified family histories by adding one FDR diagnosis of BC to cases and subtracting one FDR diagnosis from controls, selected uniformly at random. Random patient selections were repeated 1,000 times and results were reported as medians of 1,000 iterations.
RESULTS
We identified 95,561 eligible patients (Table 1) . A total of 6,775 pathogenic mutations were detected in 6,626 (7%) patients (Table 2 ). This includes 2,771 mutations detected in 2,701 (10%) BCaffected patients, and 715 mutations in 701 (14%) OC-affected patients. Overall, 3,007 (44%) mutations were in BRCA1/2 and 3,768 (56%) were in other genes.
Multivariable Logistic Regression Models
Eight genes were significantly associated with BC: ATM, BARD1, BRCA1, BRCA2, CHEK2, PALB2, PTEN, and TP53 (Table 3 and Fig 1) . There was no significant BC risk associated with CDH1. As an exploratory analysis, we constructed a multivariable model (as described in the Methods section) with lobular breast cancer as the dependent variable, which showed a strong association of CDH1 with lobular breast cancer (Table 3) . Eleven genes were significantly associated with OC: ATM, BRCA1, BRCA2, BRIP1, MLH1, MSH6, MSH2, NBN, RAD51C, RAD51D, and STK11 (Table 3 and Fig 1) .
Matched Case-Control Analyses
Overall, 19,056 patients were eligible as BC cases, 3,695 patients as OC cases, and 51,200 patients as cancer-free controls. We identified matched controls for 15,826 BC and 2,731 OC cases.
Risk estimates from matched case-control analyses and multivariable models were consistent (Table 3, Table 4 , and Fig 1) . Matched analyses detected significant BC associations for the same eight genes as with multivariable modeling (Table 3, Table 4 , and Fig 1) . Matched analyses produced similar OC risk estimates relative to multivariable models, but statistical significance was achieved for only three genes (BRCA1, BRCA2, and RAD51C; Table 4 and Fig 1) .
Sensitivity Analysis
Cumulative BC risk estimates for BRCA1 and BRCA2 were compared with published estimates from several study designs (Fig 2) . The adjusted BC risk estimates showed close agreement with the literature at earlier ages and diverged slightly at older ages, with lower risk. This is consistent with a more prominent role of family cancer history in overall BC risk at older ages. Accounting for family history resulted in a slightly lower adjusted BC risk compared with the unadjusted published estimates.
We also investigated the impact of over-or underreporting family cancer history for BRCA1 and PALB2. Sensitivity analyses showed that risk estimates will be inflated if family history is overreported by controls and/or under-reported by cases, which would cause more severe cases to be matched to less severe controls. When the hypothesized differential reporting was reversed by increasing family history among controls and decreasing it among cases, the ORs decreased (Data Supplement). However, the magnitude of this change was modest. When family history was modified in 50% of cases and 50% of controls, the OR decreased from 5.91 (95% CI, 5.25 to 6.67) to 3.91 (95% CI, 3.47 to 4.40) for BRCA1 and from 3.39 (95% CI, 2.79 to 4.12) to 2.30 (95% CI, 1.89 to 2.81) for PALB2 (Data Supplement).
DISCUSSION
To our knowledge, this is the largest study to date of patients tested clinically with a multiple-gene panel. We used multivariable modeling and matched case-control approaches to estimate mutation penetrance for 25 cancer-associated genes, adjusting for age, race/ethnicity, and family cancer history. Among mutations associated with significantly increased BC risk, the highest risk was associated with BRCA1 (OR, 5.91) and the lowest with ATM (OR, 1.74). Among genes associated with significantly increased OC risk, the highest risk was with STK11 (OR, 41.9) and the lowest with ATM (OR, 1.69).
These findings begin to answer pressing questions about the magnitude of cancer risk for commonly sequenced genes, independent of family history. Eight genes were associated with increased BC risk: ATM, BARD1, BRCA1, BRCA2, CHEK2, PALB2, PTEN, and TP53. We did not observe increased BC risk with mutations in NBN, which was surprising because NBN is generally considered to be a moderate-penetrance breast cancer susceptibility gene. 16 Reports of BC risks associated with BRIP1, RAD51C, and RAD51D mutations are mixed; 38,39 our results suggest no greater than average risk. In addition, there have been some reports of increased BC incidence among individuals with mutations in the Lynch syndrome genes MSH6 and PMS2; [40] [41] [42] [43] however, our analysis showed no increased risk of BC for individuals with mutations in these genes.
We found 11 genes significantly associated with increased OC risk: ATM, BRCA1, BRCA2, BRIP1, MLH1, MSH6, MSH2, NBN, RAD51C, RAD51D, and STK11. These results are consistent with prior studies of BRCA1/2, BRIP1, RAD51C, and RAD51D and the mismatch repair genes in OC susceptibility.
17,43-52 For NBN, there has been prior speculation but no definite evidence of an OC association. 50 To our knowledge, this is the first report of increased OC risk associated with a germline ATM mutation. Given estimates that as many as 1% of BC patients and 0.5% of the general population may carry an ATM mutation, [53] [54] [55] with many having no family history of OC, defining their risk of developing OC is an urgent research priority. We did not observe an increased OC risk with BARD1 mutations, in contrast with some recent studies. 56 The estimated OC risk calculated for PALB2 was . 1; however, it did not meet our definition of significance. In light of a recent study reporting increased incidence of PALB2 mutations in women with OC, 56 additional studies will be essential to understand the contribution of PALB2 mutations to OC susceptibility.
Previous studies of BC and OC gene penetrance have used various designs, including kin cohort and case control. 17, 18, 31, 33, [57] [58] [59] [60] [61] [62] All study designs are subject to bias. Furthermore, cancer risk estimates differ depending on how participants were ascertained. For example, family-based studies of BRCA1/2 mutation carriers in cancer genetics clinics, 59 ,60 which serve patients who have striking family histories, reported nearly two-fold-higher risk estimates than population-based studies. 17, 61 Studies that compare cases ascertained for clinical testing with general population controls (eg, the 1000 Genomes Project or the Exome Aggregation Consortium) 63, 64 will yield penetrance estimates that are falsely elevated if clinical cases are enriched for mutations over general population cases. 65 Furthermore, this false elevation may be magnified and false associations may arise as the result of more comprehensive sequencing of clinical samples. The clinical testing data set we used did not include related individuals (required for kin-cohort analysis); thus we used the two other penetrance study designs that are feasible with data of this kind, ie, multivariable logistic regression modeling and an analysis of cases matched to comparable controls from the same patient population. 66 We controlled for ascertainment bias using standard methods for confounding variables, 25 which yielded adjusted ORs that estimate the relative risk conferred by a gene mutation after accounting for family cancer history, race/ ethnicity, and age.
The concordant results of the two analytic methods we used (logistic regression and matched case/control) suggest that both adequately accounted for ascertainment bias. Compared with prior studies that did not control for family history, our approach yields cancer risk estimates for well-characterized genes (eg, BRCA1/2; Fig 2) that are slightly lower than the average but still overlap with previously reported results. [31] [32] [33] [34] [35] The risk estimates from the current study are derived from, and thus relevant to, most patients undergoing clinical genetic testing. Some patients with exceptionally strong family cancer histories may have higher risks than reported here. Ongoing research efforts that aim to personalize cancer risk assessment, by incorporating unbiased mutation penetrance estimates with a patient's family history and other risk-modifying factors, are essential to improving the quality of preventive care.
Our study has limitations. As a real-world sample of clinically tested patients, participants were not accrued according to the rigorous eligibility criteria of a clinical trial. Family history data were obtained from requisition forms completed by ordering physicians and genetic counselors. Given the large sample, confirmation of family history through patient report or medical records was not feasible. A potential bias may be differential reporting of family history among cases versus controls. For example, patients with cancer often meet guidelines for genetic testing regardless of their family history; thus it is possible that family history was reported less completely by ordering clinicians for cases than for controls (who generally meet guidelines for insurance coverage of testing only because of their relatives' cancer histories). To investigate the potential impact of such a bias, we conducted sensitivity analyses assuming differential family history reporting between cases and controls (Data Supplement). We found modest differences in penetrance estimates even across improbable simulations in which > 50% of cases and controls are affected. In addition, family history information did not include the number of unaffected relatives, which prevents an analysis of the strength of family cancer history versus family size. The limitations of this study are balanced by its considerable strengths, most notably its size (N = 95,561) and representation of patients who receive multiple-gene panel testing under the routine conditions of clinical practice. The results cannot replace controlled studies of mutation penetrance in unselected patients with BC, who lack early age at onset or strong family history; such research will require analysis of population-based cohorts, which is underway. Studies with complementary designs, such as kin-cohort and other family-based approaches, will be important for comparison with the results provided here. Nonetheless, the results of this study offer robust estimates of mutation penetrance that are relevant to most patients seen for hereditary BC and/or OC risk assessment.
Implications for Patient Care
Guideline organizations, including the American Cancer Society and American College of Radiology, have designated an absolute lifetime BC risk of > 20% to 25%, or two times the average woman's lifetime risk, as the threshold for adding breast magnetic resonance imaging (MRI) to annual mammography screening. 21, 23 This recommendation is based on studies that designate a two-fold risk increase as the threshold value at which highly sensitive MRI screening is effective from both a clinical and a cost standpoint. 23, 67 This risk-based framework underlies the current gene-specific breast screening recommendations of the National Comprehensive Cancer Network, which added ATM, CHEK2, and PALB2 mutations as new criteria for breast screening by MRI in 2014. 20, 24 The BC risk estimates that we present for ATM, CHEK2, and PALB2 mutations are consistent with these screening guidelines.
Because prophylactic surgery is invasive and irreversible, the burden of proof should be more stringent than for a screening intervention. If confirmed, the three-fold or greater OC risk estimates presented here for BRIP1 and RAD51C/D would support their recent addition to guidelines criteria for risk-reducing salpingo-oophorectomy. 20 However, the lower estimates of OC risk with ATM and NBN are less clearly an indication for prophylactic surgery. If confirmed, the current results may justify a case-by-case discussion of OC risk-reduction approaches with women who carry these mutations, considering family history as well as these genespecific risk estimates.
In conclusion, we observed and quantified significant BC risks associated with eight genes and OC risks associated with 11 genes that are commonly sequenced on multiple-gene panels. These results may be used to inform genetic counseling, as well as screening and prevention approaches, among patients being evaluated for HBOC susceptibility. ascopubs.org/journal/po JCO™ Precision Oncology 9
